The Motley Fool··Seena HassounaENAVATE's Zenas Stake Surge Masks Real Story: Obexelimab Pipeline
ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.
ZBIOFDA approvalautoimmune diseases